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Abstract
Background: Antimicrobial resistance (AMR) in Neisseria gonorrhoeae is a major public health concern worldwide. In
Vietnam, knowledge regarding N. gonorrhoeae prevalence and AMR is limited, and data concerning genetic
characteristics of N. gonorrhoeae is totally lacking. Herein, we investigated the phenotypic AMR (previous, current
and possible future treatment options), genetic resistance determinants for extended-spectrum cephalosporins
(ESCs), and genotypic distribution of N. gonorrhoeae isolated in 2011 in Hanoi, Vietnam.
Methods: N. gonorrhoeae isolates from Hanoi, Vietnam isolated in 2011 (n = 108) were examined using
antibiograms (Etest for 10 antimicrobials), Neisseria gonorrhoeae multi-antigen sequence typing (NG-MAST), and
sequencing of ESC resistance determinants (penA, mtrR and penB).
Results: The levels of in vitro resistance were as follows: ciprofloxacin 98%, tetracycline 82%, penicillin G 48%,
azithromycin 11%, ceftriaxone 5%, cefixime 1%, and spectinomycin 0%. The MICs of gentamicin (0.023-6 mg/L),
ertapenem (0.002-0.125 mg/L) and solithromycin (<0.016-0.25 mg/L) were relatively low. No penA mosaic alleles
were found, however, 78% of the isolates contained an alteration of amino acid A501 (A501V (44%) and A501T
(34%)) in the encoded penicillin-binding protein 2. A single nucleotide (A) deletion in the inverted repeat of the
promoter region of the mtrR gene and amino acid alterations in MtrR was observed in 91% and 94% of the isolates,
respectively. penB resistance determinants were detected in 87% of the isolates. Seventy-five different NG-MAST STs
were identified, of which 59 STs have not been previously described.
Conclusions: In Vietnam, the highly diversified gonococcal population displayed high in vitro resistance to
antimicrobials previously recommended for gonorrhoea treatment (with exception of spectinomycin), but resistance
also to the currently recommended ESCs were found. Nevertheless, the MICs of three potential future treatment
options were low. It is essential to strengthen the diagnostics, case reporting, and epidemiologic surveillance of
gonorrhoea in Vietnam. Furthermore, the surveillance of gonococcal AMR and gonorrhoea treatment failures is
imperative to reinforce. Research regarding novel antimicrobial treatment strategies (e.g., combination therapy) and
new antimicrobials is crucial for future treatment of gonorrhoea.
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Background
Infections caused by Neisseria gonorrhoeae are major pub-
lic health problems globally. In 2008, the World Health
Organization (WHO) estimated 106 million new cases of
gonorrhoea among adults worldwide. This places gonor-
rhoea as the most common bacterial sexually transmitted
infection (STI), that is, together with Chlamydia tracho-
matis infections also estimated to 106 million cases. The
highest gonorrhoea incidence was in the WHO Western
Pacific region (WPR), estimated to 42 million cases [1]. In
general, the highest rates of gonorrhoea have been found
in developing countries and especially in lower socio-
economic groups, men who have sex with men (MSM),
commercial sex workers (CSWs) and their clients [1,2].
N. gonorrhoeae has developed resistance to all antimi-
crobials previously recommended as first-line treatment of
gonorrhoea, e.g. penicillins, tetracyclines and fluoroquino-
lones, as well as macrolides such as erythromycin and
azithromycin. Extended-spectrum cephalosporins (ESCs)
are currently the recommended first-line antimicrobials in
most countries worldwide. However, recent two decades
in vitro resistance also to ESCs have emerged and spread
[2-6]. Verified treatment failures with the oral ESC cefix-
ime have been reported in Japan and recently in several
European countries [6-12]. With the injectable ESC cef-
triaxone, a few cases of confirmed treatment failure of
pharyngeal gonorrhoea have been reported [13-16] and
most worryingly the first three extensively-drug resistant
(XDR) [5] gonococcal strains with high-level resistance to
ceftriaxone have been described [9,16,17]. Ceftriaxone is
also the last remaining option for empirical first-line anti-
microbial monotherapy of gonorrhoea. In this developing
situation, including the fear that gonorrhoea may become
untreatable, the WHO [18], European Centre for Disease
Prevention and Control (ECDC) [19] and Centers for
Disease Control and Prevention (CDC), USA [20] have
published action/response plans to combat and mitigate
the widespread of multidrug-resistant gonorrhoea. How-
ever, even if these action/response plans will be fully
implemented ultimately it is vital to develop new treatment
strategies and particularly novel antimicrobials. Gentamicin,
ertapenem and solithromycin have been previously investi-
gated and may be effective treatment alternatives, in anti-
microbial monotherapy and particularly in combination
therapy [6,21-25].
Mutations in the penA gene encoding the penicillin-
binding protein 2 (PBP2) is the main determinant for de-
creased susceptibility and resistance to ESCs. Acquisition of
a penA mosaic gene or an alteration of amino acid A501 in
PBP2 result in a lower affinity for ESCs and consequently a
decreased ESC susceptibility [6,9,16,26-32]. Mutations in
the promoter or coding sequence of the repressor gene
mtrR cause over-expression of the MtrCDE efflux pump
system that export the ESCs out from the cell. This further
decreases the susceptibility to ESCs [6,9,16,28,32-35]. Al-
terations of amino acid G101 and A102 in the porin
PorB1b (the penB resistance determinant), which is en-
coded by the porB1b gene, result in decreased perme-
ability and further decreased susceptibility to ESCs
[6,9,16,28,32,34,36,37]. There is still at least one unknown
non-transformable ESC resistance determinant [6,9,16,32].
Historically, antimicrobial resistance (AMR) in N. gonor-
rhoeae appears to mostly have emerged in WHO WPR and
subsequently spread globally, by sex tourists and travellers
[2,4-6]. In WHOWPR, Vietnam is the easternmost country
on the Indochina Peninsula in Southeast Asia; bordering to
China, Laos, and Cambodia and with an estimated popu-
lation of about 90 millions. In Vietnam, for treatment of
gonorrhoea ceftriaxone 250 mg × 1 intramuscularly is the
recommended first-line and cefixime 400 mg × 1 orally the
recommended second-line. However, a wide variety of anti-
microbials such as penicillins, fluoroquinolones, macrolides,
and spectinomycin may still be used for treatment. Worry-
ingly, the knowledge regarding N. gonorrhoeae AMR in
Vietnam is limited, and data concerning genetic charac-
teristics (molecular epidemiology and genetic resistance
determinants) is totally lacking. Regarding prevalence of
gonorrhoea in Vietnam, some few studies have showed low
prevalences among women of reproductive age [38,39],
one study of female sex workers described a prevalence of
14.9% [40] and one study of men who have sex with men
reported a prevalence of 1.8% for gonorrhoea and 4.7% for
gonorrhoea/chlamydia [41]. In general, the gonorrhoea
diagnostics in Vietnam is suboptimal and individuals com-
monly prefer private healthcare providers, self-medication
or treatment by drug sellers instead of accessing public
services [38,42]. Accordingly, no reliable national incidence
data in regard to bacterial STIs, including gonorrhoea, exist
because the STI diagnostics (quality including availability),
case reporting (particularly among private health care pro-
viders) and epidemiological surveillance are suboptimal.
The aims of the present study were to investigate the
phenotypic AMR (previous, current and possible future
treatment options), genetic ESC resistance determinants,
and genotypic distribution of N. gonorrhoeae isolated in
2011 in Hanoi, Vietnam.
Methods
Neisseria gonorrhoeae isolates
All 108N. gonorrhoeae isolates were obtained at the
National Hospital of Dermatology and Venerology, Hanoi,
Vietnam from January to September 2011. The isolates
were cultured from consecutive symptomatic gonorrhoea
patients; 19 females, 85 males, and four patients lacking
data of sex and age. Mean age for the females was 28.5 years
(median age: 26.5 years; range: 6 to 40 years) and for the
males 29 years (median age: 27 years; range: 18 to 60 years).
Of the patients, 72% were from Hanoi, 18% from other Red
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river delta provinces, 6% from different other provinces,
and for 4% no information regarding place of accommoda-
tion was available.
All isolates were lyophilized and sent to the WHO Col-
laborating Centre for Gonorrhoea and Other STIs, Örebro
University Hospital, Sweden, for species confirmation by
culture on selective agar media, a sugar utilization test and
the PhadeBact GC Monoclonal test (Bactus AB, Solna,
Sweden), and subsequently preserved as previously des-
cribed [43]. All examined gonococcal isolates were cul-
tured and stored as part of the routine diagnostics
(standard care) and no patient identification information
was used in the study.
Antimicrobial susceptibility testing
The minimum inhibitory concentration (MIC; mg/L) of
cefixime, ceftriaxone, penicillin G, azithromycin, ciproflo-
xacin, spectinomycin, tetracycline, gentamicin, and ertape-
nem were analysed using the Etest method (bioMerieux
AB, Solna, Sweden), according to the instructions from
the manufacturer, and to solithromycin with agar dilution
method, in accordance with the Clinical and Laboratory
Standards Institute (CLSI (M100-S22)). All results were
interpreted using whole MIC dilutions and where available,
breakpoints for susceptibility (S) and resistance (R) accord-
ing to The European Committee on Antimicrobial Suscep-
tibility Testing (EUCAST [www.eucast.org]) were used
(Table 1). For gentamicin, ertapenem and solithromycin,
no breakpoints are stated by any organization.
Isolation of genomic DNA
Bacterial DNA was isolated in the robotized NorDiag
Bullet instrument (NorDiag ASA Company, Oslo, Norway)
using the BUGS’n BEADS™ STI-fast kit (NorDiag ASA
Company, Oslo, Norway), according to the instructions
from the manufacturer.
Molecular epidemiological typing
N. gonorrhoeae multiantigen sequence typing (NG-MAST)
was performed as previously described [44,45]. NG-MAST
allele numbers of the more variable segments of porB and
tbpB, and sequence types (STs) were assigned using the
NG-MAST website (www.ng-mast.net).
Sequencing of genetic ESC resistance determinants
Detection of ESC resistance determinants in N. gonor-
rhoeae, i.e. penA mosaic alleles, alterations of A501 in
PBP2, mutations in the promoter and/or coding sequence
of the mtrR gene, and the penB resistance determinant,
were performed by sequencing as previously described
[34,45].
Sequence alignments
Multiple-sequence alignments of nucleotide sequences
and the deduced corresponding amino acid sequences
were performed in the software BioEdit Sequence Align-
ment Editor version 7.0.9.0 with manual adjustment.
Results
Antimicrobial susceptibility
The antimicrobial susceptibility of all isolates are sum-
marised in Table 1.
Briefly, the levels of in vitro resistance were as follows:
ciprofloxacin 98%, tetracycline 82%, penicillin G 48%, azi-
thromycin 11%, ceftriaxone 5%, cefixime 1%, and spectino-
mycin 0%. For gentamicin (MIC range: 0.023–6 mg/L),
ertapenem (0.002–0.125 mg/L) and solithromycin (<0.016–
0.25 mg/L) there are no breakpoints stated by any
Table 1 Antimicrobial susceptibility of 108 Neisseria gonorrhoeae isolates from Hanoi, Vietnam in 2011
Antimicrobial (Breakpoints (mg/L)) Susceptible no. (%) Intermediate no. (%) Resistant no. (%)
Ciprofloxacin (S≤ 0.032, I = 0.064, R > 0.064)* 2 (2) 0 106 (98)
Tetracycline (S≤ 0.5, I = 1.0, R > 1.0)* 7 (6) 13 (12) 88 (82)
Penicillin G (S≤ 0.064, I = 0.125-1.0, R > 1.0)* 2 (2) 54 (50) 52 (48)
Azithromycin (S≤ 0.25, I = 0.5, R > 0.5)* 67 (62) 29 (27) 12 (11)
Ceftriaxone (S≤ 0.125, I = NA, R > 0.125)* 103 (95) NA 5 (5)
Cefixime (S≤ 0.125, I = NA, R > 0.125)* 107 (99) NA 1 (1)
Spectinomycin (S≤ 64, I = NA, R > 64)* 108 (100) NA 0
MIC range (mg/L) MIC50 (mg/L) MIC90 (mg/L)
Gentamicin** 0.032–8 4 4
Ertapenem** 0.002–0.125 0.012 0.032
Solithromycin** <0.016-0.25 0.064 0.125
NA, not applicable.
* Breakpoints for susceptible (S ≤ x mg/L) and resistant (R > y mg/L) according to The European Committee on Antimicrobial Susceptibility Testing (EUCAST; www.
eucast.org).
** Breakpoints not stated by any organization.
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organization, however, the MICs were relatively low, indi-
cating a susceptible gonococcal population (Table 1).
According to the breakpoints stated by the EUCAST,
five (5%) isolates displayed in vitro resistance to ceftriax-
one (all having MIC = 0.25 mg/L) and 1 (1%) to cefixime
(MIC = 0.25 mg/L). However, in Japan also gonococcal
isolates with cefixime MIC of 0.125 mg/L have resulted
in treatment failure with cefixime (200 mg × 2) [7]. Ac-
cordingly, isolates with an ESC MIC of 0.125 mg/L
might be considered as having at least an in vitro de-
creased susceptibility to ESCs. In the present study, the
number of isolates with an ESC MIC ≥ 0.125 mg/L were
high, i.e., 30 (28%) and 9 (8%) for ceftriaxone and cefix-
ime, respectively.
ESC genetic resistance determinants (penA, mtrR and penB)
The NG-MAST STs, presence of ESC resistance deter-
minants, and MICs of ESCs among all the isolates with
in vitro resistance or decreased susceptibility to ESCs
(MIC ≥ 0.125 mg/L; n = 30) are summarized in Table 2.
None of the 30 isolates with in vitro resistance or
decreased susceptibility (MIC ≥ 0.125 mg/L) to ceftriaxone
(n = 30) and cefixime (n = 9) contained a penA mosaic
allele. However, 17 (57%) of those 30 isolates contained an
A501T alteration and 12 (40%) had an A501V alteration in
PBP2, and all 30 isolates contained mtrR and penB resist-
ance determinants (Table 2).
Moreover, in the entire material (108 isolates) no isolates
containing a penA mosaic allele were found. However, 47
(44%) of the isolates contained a PBP2 A501V alteration
and 37 (34%) a PBP2 A501T alteration. The alleles, accord-
ing to the previously published numbering of PBP2 amino
acid sequences in N. gonorrhoeae [16], were PBP allele
XVIII (n = 37), A501V New allele (n = 28), XIII (n = 13),
XXI (n = 3), XXXIII (n = 2), and A501V New allele (n = 1).
The MICs of cefixime and ceftriaxone for the isolates with
PBP2 A501 alterations ranged from <0.016–0.25 mg/L
(mean MIC: 0.064 mg/L) and 0.016–0.25 mg/L (mean
MIC: 0.064 mg/L), respectively.
A single nucleotide (A) deletion in the inverted repeat
of the promoter region of the mtrR gene was observed
in 98 (91%) of the 108 isolates. Amino acid alterations in
MtrR were found in 102 (94%) isolates. Accordingly, 45
(42%) had alterations in amino acid residue H105, 30
(28%) in A39, and 27 (25%) in G45. Furthermore, the
recently described C-to-T transition 120 bp upstream of
the mtrC start codon (termed mtr120) that results in a
consensus −10 element, a novel promoter for mtrCDE
transcription and accordingly increased expression of
the MtrC-MtrD-MtrE efflux pump was found in four
(4%) isolates [35].
Alterations in amino acid residues G101 and/or A102
of PorB1b (penB resistance determinant) were detected
in 94 (87%) of the isolates. All those isolates possessed
an altered G101, and 84 (78%) contained an additional
alteration of A102.
Molecular epidemiological characterisation
The 108 isolates were assigned to 75 different NG-MAST
STs. Fifty-nine (79%) of these STs have not been previously
described. The most prevalent ST was ST4787 (n = 11),
followed by ST7720 (n = 5), ST7741 (n = 4), ST7724 (n = 3),
and ST7155 (n = 3). Of those STs, all except ST4787 were
Table 2 Neisseria gonorrhoeae with decreased susceptibility or resistance to cefixime or ceftriaxone (≥0.125) isolated in
Hanoi, Vietnam in 2011 (n = 30)
NG-MAST Minimum inhibitory
concentration
penA alteration mtrR alteration PorB1b (penB
alteration)
Cefixime Ceftriaxone A501 alteration
(penA allele [16])
A-deletion in promoter region MtrR coding region G101 A102
ST4787 (n = 1) 0.25 0.25 T (XVIII) Yes A39T K D
ST4787 (n = 2) 0.125 0.25 T (XVIII) Yes A39T K D
ST4787 (n = 1) 0.125 0.125 V (A501 New**) Yes H105Y K D
ST4787 (n = 3) 0.064 0.125 T (XVIII) Yes A39T K D
ST4787 (n = 1) 0.032 0.125 T (XVIII) Yes A39T K D
ST7159 (n = 2) 0.064 0.125/0.25 T (XVIII) Yes D79N T86A H105Y K D
ST4676 (n = 1) 0.125 0.25 T (XVIII) Yes H105Y K G
3 STsa (n = 4) 0.125 0.125 T (XVIII) Yes A39T K/Db D/Gb
12 STs (n = 15) 0.064 0.125 T/V/WTc Yes A39T G45D H105Yd K/D/Te D/G/WTe
NG-MAST, Neisseria gonorrhoeae multiantigen sequence typing; ST, sequence type.
a ST7739 (n = 2), ST7160 (n = 1) and ST7741 (n = 1).
b G101D/A102G (n = 2) and G101K/A102D (n = 1).
c A501V New** (n = 9), XVIII (n = 3), XIII (n = 2) and XII (n = 1).
d H105Y (n = 8), A39T (n = 4), and G45D (n = 3).
e G101K/A102D (n = 11), G101D/A102G (n = 2), G101D/WT (n = 1), G101T/A102D (n = 1).
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novel STs. Twelve STs contained two isolates and 58 STs
were represented by single isolates (Table 3).
Eight (73%) of the ST4787 isolates (n = 11) displayed
in vitro resistance or decreased susceptibility to ceftriaxone
(MIC ≥ 0.125 mg/L) and four (36%) of them resistance or
decreased susceptibility to cefixime (MIC ≥ 0.125 mg/L).
Ten (91%) of the ST4787 isolates contained an identical
A501T altered PBP2 allele (XVIII), a single nucleotide (A)
deletion in the mtrR promoter, A39T alteration in MtrR
and penB (G101K/A102D) (Table 2).
Discussion
In the present study, the susceptibility to previous, current
and possible future antimicrobial treatment options in
N. gonorrhoeae isolated in 2011 in Vietnam were studied.
Exceedingly high prevalence of resistance was observed
for previous first-line antimicrobials such as ciprofloxacin
(98%), tetracycline (82%) and penicillin G (48%), but also
relatively high for azithromycin (11%) (Table 1). This is in
accordance with previous studies from other countries in
WHO WPR such as Japan, The Philippines, China, Hong
Kong, Korea and Taiwan [4,46-51], South Asia, e.g., India,
Pakistan, Thailand, Sri Lanka and Bhutan [47,52,53], and
many other regions globally [3-6,18,19,54-58]. None of
these antimicrobials can be recommended for first-line
empiric therapy of gonorrhoea in Vietnam as well as in
most parts of the world.
Most worryingly, 5% of the gonococcal isolates in
Vietnam displayed in vitro resistance to ceftriaxone and
1% to cefixime (Table 1). Furthermore, in total 30 (28%)
and 9 (8%) displayed in vitro resistance or decreased
susceptibility (MIC ≥ 0.125 mg/L) to ceftriaxone and
cefixime, respectively (Table 2). All except one of these
30 isolates contained an A501 alteration in PBP2, and all
30 comprised mtrR and penB resistance determinants.
All these resistance determinants have previously been
reported as associated with decreased susceptibility and
resistance to ESCs [3,5,6,9-11,14-17,25-32,34,51,58,59].
However, in Vietnam no isolates with a mosaic PBP
allele, which has been strongly associated with decreased
susceptibility and resistance to ESCs in many countries,
was found [3,5,6,31,32,58]. The predominance of A501-
altered penA alleles in a gonococcal population with
in vitro resistance and decreased susceptibility to ESCs
as observed in Vietnam has also been previously described
in publications from other countries such as Korea [28] and
Australia [59,60]. In the present study, the MICs of cefixime
and ceftriaxone for the isolates with PBP2 A501 alterations
ranged from <0.016–0.25 mg/L and 0.016–0.25 mg/L, re-
spectively. This large variety in the MICs of ESCs among
these isolates could not be explained by the presence or
absence of other resistance determinants such as mtrR
and penB. The reasons for the highly variable ESC MICs
of isolates with A501-altered PBP2 remain unknown, but
Table 3 Minimum inhibitory concentrations (MICs, mg/L)
of cefixime and ceftriaxone for Neisseria gonorrhoeae
(n = 108) isolated in Hanoi, Vietnam in 2011
NG-MAST ST
(No. of isolates)
Anti-microbial No. of isolates with MIC (mg/L):
≤0.016 0.032 0.064 0.125 0.25
4787 (11) IX 3 4 3 1
TX 3 5 3
7720 (5)a IX 1 4
TX 5
7741 (4)a IX 3 1
TX 4
7155 (3)a IX 1 2
TX 2 1
7724 (3)a IX 3
TX 3
3493 (2) IX 2
TX 2
7139 (2)a IX 2
TX 2
7140 (2)a IX 1 1
TX 2
7159 (2)a IX 2
TX 1 1
7718 (2)a IX 2
TX 2
7722 (2)a IX 2
TX 2
7731 (2)a IX 2
TX 2
7734 (2)a IX 2
TX 1 1
7735 (2)a IX 2
TX 1 1
7736 (2)a IX 1 1
TX 2
7739 (2)a IX 2
TX 2
7748 (2)a IX 1 1
TX 1 1
Unique STs (58)b IX 15 16 25 2
TX 12 15 20 10 1
NG-MAST, Neisseria gonorrhoeae multiantigen sequence typing; ST,
sequence type;
MIC, minimum inhibitory concentration; IX, cefixime; TX, ceftriaxone.
aNew sequence types found in the present study.
bUnique STs represented by single isolates.
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possibly the isolates with higher ESC MICs also contain
the unknown non-transformable penicillin and cephalo-
sporin resistance determinant “factor X” [6,9,16,32]. Ac-
cordingly, detection of the currently known ESC genetic
resistance determinants (penA mosaic allele or alteration
of A501 in PBP2, mtrR and penB) does not strictly reflect
the exact MICs of ESCs and, accordingly, cannot replace
traditional culture-based AMR testing (which needs to be
strengthened worldwide) or be used in the management
of clinical patients. However, detection of genetic resistance
determinants combined with molecular epidemiological
typing (NG-MAST) can still be valuable for surveillance
purposes, i.e. to monitor the emergence and spread of
isolates with decreased susceptibility or resistance to ESCs,
enhancing our knowledge regarding the effects on ESC
MICs of different penA alleles, etc. The present study
shows that the prevalence of gonococcal isolates with
phenotypic and genetic resistance or decreased susceptibil-
ity to ESCs in Vietnam is high. Longitudinal studies in
Vietnam examining the ESC MICs over time supplemen-
ted by determination of genetic resistance determinants
would be exceedingly valuable.
Disquietingly, despite full implementation of the ac-
tion/response plans recently launched [18-20], ultimately
new treatment strategies and particularly novel antimi-
crobials are essential to develop. In the United Kingdom
[61], Europe [62] and USA [63], the recently revised
treatment guidelines all recommend dual antimicrobial
therapy (mainly with ceftriaxone plus azithromycin). How-
ever, in vitro and in vivo resistance to both ceftriaxone and
azithromycin have already been verified and dual anti-
microbial therapy may not be feasible and/or affordable in
all less-resourced settings. Accordingly, new antimicrobials
for treatment of gonorrhoea are essential to develop. There
are few new compounds in sight [3,6,16,64]. The new
fluoroketolide solithromycin (class: macrolides) has re-
cently been investigated and showed an activity superior to
that of most other antimicrobials previously or currently
recommended for treatment of gonorrhoea [23]. In the
present study, despite that 11% (27%) of the isolates were
resistant (intermediate resistance) to azithromycin the
MIC range of solithromycin was only <0.016–0.25 mg/L
and MIC90 was 0.125 mg/L. Accordingly, these results fur-
ther support solithromycin as a possible future option for
single and particularly dual antimicrobial therapy of gonor-
rhoea. Ertapenem, a parenteral 1-β-methyl-carbapenem,
has in a previous study shown advantages over ceftriaxone
for ceftriaxone-resistant isolates [25]. In the present study,
all 30 isolates with in vitro resistance (n = 5) and decreased
susceptibility (n = 25) to ceftriaxone displayed ertapenem
MIC values ranging from 0.016 mg/L to 0.032 mg/L
(Table 2), and the MIC90 for all isolates was 0.032 mg/L.
Finally, the aminoglycoside gentamicin has been used for
nearly two decades in Malawi to treat gonorrhoea (mainly
in syndromic management together with doxycycline), with
a remained high in vitro susceptibility in the gonococcal
populations [21,24]. An evaluation of gentamicin in vitro
susceptibility of N. gonorrhoeae isolates in Europe showed
that 95% of 1366 isolates were distributed within a narrow
MIC range of 4–8 mg/L [65]. In the present study, the
MIC range was 0.032–6 mg/L and MIC90 was 4 mg/L.
There are yet no international interpretative criteria for
MICs of solithromycin, ertapenem or gentamicin. How-
ever, in studies from Malawi breakpoints have been sug-
gested, that is, susceptible: MICs ≤ 4 mg/L, intermediate
susceptible: MIC = 8–16 mg/L and resistant: MICs ≥
32 mg/L [21].
Finally, using NG-MAST the present study showed a di-
versified population of N. gonorrhoeae in Hanoi, Vietnam
during 2011, with 75 different NG-MAST STs among the
108 isolates. The high number of unique STs (n = 58) and
STs that have not been described earlier (n = 59) may be
associated with suboptimal diagnostics (only random gon-
orrhoea patients and/or isolates are identified), contact
tracing (sexual contacts having the identical ST are not
traced) and epidemiological surveillance (sexual transmis-
sion chains spreading a single ST are not identified or fol-
lowed-up), STs evolved locally in Vietnam (STs are not
previously described because no NG-MAST studies have
previously been performed in the country) or imported
from abroad. However, some minor ST clusters caused by
clonal spread of, e.g. ST4787 (n = 11), ST7720 (n = 5) and
ST7741 (n = 4) were identified which indicate some sexual
transmission chains. Of the eleven ST4787 isolates, eight
displayed in vitro resistance or decreased susceptibility to
ceftriaxone and all eleven isolates showed A501 alteration
in PBP2 as well as contained mtrR and penB resistance
determinants.
Conclusions
N. gonorrhoeae isolated in Vietnam during 2011 showed
a high genetic diversity and high levels of in vitro resist-
ance to antimicrobials previously recommended for gon-
orrhoea treatment, such as ciprofloxacin, tetracycline,
penicillin G and azithromycin. Furthermore, 5% (28%) of
the isolates were in vitro resistant (had a decreased sus-
ceptibility) to ceftriaxone, currently the recommended
drug of choice for treatment of gonorrhoea. Nevertheless,
no resistance to spectinomycin, which remains available
in Vietnam, was found and the MICs of three potential
future treatment options were low. Research regarding
novel antimicrobial treatment strategies (e.g., combination
therapy) and new antimicrobials is crucial for future treat-
ment of gonorrhoea.
Finally, it is of great importance to strengthen the
N. gonorrhoeae diagnostics, case reporting, and surveillance
of epidemiology, AMR as well as gonorrhoea treatment fail-
ures in Vietnam.
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